Suraksha Diagnostic Ltd

Suraksha Diagnostic Limited announced its audited financial results for the quarter and full year ended March 31, 2026. The company reported a 23% increase in total income to ₹3,136 million for FY26, with EBITDA rising by 16% to ₹986 million. EPS stood at ₹6.2, and profit after tax increased by 1% to ₹314 million. In Q4 FY26, total income grew by 24.7% to ₹821.97 million, and EBITDA increased by 25.7% to ₹251.55 million. The company expanded its network by adding new hubs and spoke centers during the fiscal year.

Suraksha Diagnostic Ltd's Board of Directors has recommended a dividend of ₹0.50 per equity share (25% of face value of ₹2) for the financial year 2025-26, subject to shareholder approval at the upcoming 21st Annual General Meeting. The record date for determining dividend entitlement is set for August 26, 2026, and payment will be made within the statutory period if approved. The board also approved the audited financial results for the year ended March 31, 2026, and other routine matters including auditor appointments.

Suraksha Diagnostic Ltd has appointed M/s Suresh Surana & Associates LLP as its Internal Auditor for the financial year 2026-27. This decision was made during a Board of Directors meeting held on May 21, 2026, where the board also approved the audited financial results for the year ended March 31, 2026, recommended a dividend of ₹0.50 per share, and approved the notice for the 21st AGM.

Suraksha Diagnostic Ltd has re-appointed M/s S Chhaparia & Associates as Cost Auditor for the financial year ending March 31, 2026. This decision was made during a Board of Directors meeting on May 21, 2026, where the board also approved the audited financial results for the same period and recommended a dividend of ₹0.50 per equity share. The appointment is subject to shareholder ratification at the upcoming 21st Annual General Meeting (AGM).

Suraksha Diagnostic Ltd's board approved the audited financial results for the quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹0.50 per equity share (25%) for FY26, subject to shareholder approval. The 21st AGM will be held on September 2, 2026, via video conferencing. The record date for dividend entitlement is August 26, 2026. The board also approved the appointment of internal and cost auditors for FY27.

Suraksha Diagnostic Ltd's board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. A dividend of ₹0.50 per equity share (25%) for FY26 was recommended, subject to shareholder approval. The 21st AGM will be held on September 2, 2026, via video conferencing. August 26, 2026, is fixed as the record date for dividend entitlement. M/s. Suresh Surana & Associates LLP appointed as Internal Auditor for FY27.

Suraksha Diagnostic Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a dividend on equity shares for the same financial year. The trading window, which was closed from April 1, 2026, will re-open 48 hours after the declaration of the financial results.

Suraksha Diagnostic Ltd has announced the resignation of its Group Chief Financial Officer (CFO), Mr. K S Ravindra, who is designated as Key Managerial Personnel (KMP) of the Company. Mr. Ravindra tendered his resignation on 02 March 2026, citing personal reasons. His last working day with the Company will be on or before 31 May 2026. The Company has expressed its appreciation for Mr. Ravindra's services and his contributions during his tenure.

Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and nine months ended 31 December 2025. The company reported a 30.3% year-on-year growth in total income in Q3 FY26, with EBITDA growing by 26.1% year-on-year. The company added 12 operational centers in 9M FY26 and forayed into the high-value genomics segment with Suraksha Sutra. Despite the launch and development of new centers, the company's centers older than 2 years maintain a strong 37% EBITDA margin.

Suraksha Diagnostic Ltd has reported its financial results for the quarter and nine months ended 31 December 2025. The company's revenue for the nine months stood at INR 22,212.32 lakhs with a profit before tax of INR 3,049.53 lakhs. The company is primarily engaged in the business of diagnostic centres and has assessed the impact of the New Labour Codes, which is not material for the period. However, an ongoing dispute with the Government of Meghalaya in a step-down subsidiary is under assessment.